Posts by DAY Vision

[vc_row][vc_column][vc_column_text]Boston, Mass., January 2, 2013, /PRNewswire/ — Dilon Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify “cancer on the margin” and significantly…

[vc_row][vc_column][vc_column_text]Framingham, MA, September 27, 2012 – Dilon Devices announced today that the MarginProbe System will be used at the Agaplesion Markus Hospital, in Frankfurt, Germany.  The Agaplesion Markus Hospital is the largest breast center in the Frankfurt area, treating over 400 primary breast cancer cases annually. “In my previous work with the MarginProbe System, we…

[vc_row][vc_column][vc_column_text]Framingham, Mass., November 19, 2012 – Dilon Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration.   The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval…

[vc_row][vc_column][vc_column_text]FDA Advisory Panel Votes in Favor of Dilon Devices MarginProbe® System Gaithersburg, MD, June 22, 2012 – Dilon Devices announced today that a U.S. Food and Drug Administration (FDA) Advisory Panel voted (10 to 1) in favor of Dune’s MarginProbe System for use in breast cancer surgery, as an adjunct to current standard methods of…